DiscoverOncology Times - OncTimes TalkKEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma
KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma

KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma

Update: 2025-01-24
Share

Description

The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) drug ipilimumab for treating patients with unresectable advanced or metastatic melanoma. Results from the study were reported at the European Society for Medical Oncology (ESMO) 2024 Annual Congress, held in Barcelona, Spain.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma

KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma